title: [Another approach to targeted therapy of patients with metastatic renal carcinoma with progression in treatment with pazopanib:expert assessment by the Czech Cooperative Group for Metastatic Renal Carcinoma].
authors.affiliation: Onkologická 1.LF UK a Thomayerovy Nemocnice, Praha. tomas.buchler@ftn.cz
authors.forename: T
authors.initials: T
authors.lastname: Büchler
authors.forename: J
authors.initials: J
authors.lastname: Finek
authors.forename: J
authors.initials: J
authors.lastname: Hájek
authors.forename: I
authors.initials: I
authors.lastname: Kocák
authors.forename: K
authors.initials: K
authors.lastname: Kubácková
authors.forename: R
authors.initials: R
authors.lastname: Lakomý
authors.forename: B
authors.initials: B
authors.lastname: Melichar
authors.forename: L
authors.initials: L
authors.lastname: Petruzelka
authors.forename: A
authors.initials: A
authors.lastname: Poprach
authors.forename: M
authors.initials: M
authors.lastname: Siffnerová
authors.forename: J
authors.initials: J
authors.lastname: Tomásek
authors.forename: R
authors.initials: R
authors.lastname: Vyzula
authors.forename: M
authors.initials: M
authors.lastname: Zemanová
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000556:secondary*; D018450:Disease Progression; D006801:Humans; D007191:Indazoles; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011743:Pyrimidines / Q000627:therapeutic use*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors*; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D020533:Angiogenesis Inhibitors; D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib; D040262:Receptors, Vascular Endothelial Growth Factor